Release details

2012-06-06 14:12 CEST
  • Print
  • Share Share
no en


CellCura ASA (Oslo Axess: CELL) announces that the company has signed an agreement with Complete Fertility Center, a world class major IVF Clinic in Southampton, UK. The clinic will participate in a user oriented program using the CellCura ART Lab Solution.

"We are really pleased that a leading UK IVF clinic has chosen to become a part of our reference and development program in one of the most important European markets. Experience from Belgium also shows that local references creates new sales in local market", says Martin Beresford, CellCura's sales and marketing manager for CellCura ART Lab Solution.

"CellCura will enter into similar agreements with other leading clinics during the next months as part of a program to further strengthen our market position and sales in key markets", continues Martin Beresford.

The CellCura ART Lab Solution represents a quantum leap in laboratory efficiency and safety by combing all the steps in the IVF process into one integrated workplace. The CellCura ART Lab Solution is a technologically advanced working environment that is meeting the ART professional's documentation requirements, offering them significantly improved workflow, ergonomic and compliance with the 2004/23/EC ("cell & tissue") directive requirement. For the clinics this will result in a quicker start up time, higher productivity, safety and efficiency. Due to improved ergonomics, the strain on the laboratory staff will be significantly reduced leading to less staff on sick leave and thus better economy for the clinic.

Oslo, 06 June 2012

CellCura ASA

Lars Bredahl
Chief Executive Officer
Phone + 47 90824075

CellCura ASA is dedicated to the development and sales of cell technologies for use in assisted reproductive technology (ART) and stem cell research worldwide, representing improved safety and efficiency compared to traditional technology. CellCura is listed on the Oslo Axess market at the Oslo Stock Exchange (ticker: CELL).

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)